AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30791804 — intervention group
Group type: EXPERIMENTAL
Intervention: sifalimumab (same doses as Stage I or 600 mg IV every 4 weeks if enrolled later)
Number of subjects: 51
Study 30791804 — intervention group
Group type: EXPERIMENTAL
Intervention: sifalimumab
Number of subjects: 51
Study 30248039 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulligan mobilization with conventional physiotherapy
Number of subjects: 30
Study 30248039 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (Control)
Number of subjects: 30
Study 28137336 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week group Cognitive Behavioural Therapy for perfectionism (CBT-P)
Number of subjects: 11
Study 28137336 — intervention group
Group type: COMPARATOR
Intervention: 8-week waitlist followed by CBT-P
Number of subjects: 11
Study 23828493 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + aPDT
Number of subjects: 20
Study 23828493 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 20
Study 23275597 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipeline embolization device
Number of subjects: 96
Study 21905402 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NovaMin toothpaste
Number of subjects: 0
Study 21905402 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% arginine toothpaste
Number of subjects: 0
Study 21905402 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study 21905402 — intervention group
Group type: COMPARATOR
Intervention: Control toothpaste
Number of subjects: 0
Study 19395071 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative morphine-bupivacaine PCEA
Number of subjects: 135
Study 19395071 — intervention group
Group type: COMPARATOR
Intervention: Postoperative intravenous morphine PCA
Number of subjects: 135
Study 16882803 — intervention group
Group type: EXPERIMENTAL
Intervention: Car bed
Number of subjects: 67
Study 16882803 — intervention group
Group type: COMPARATOR
Intervention: Car safety seat
Number of subjects: 67
Study 11425054 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 232
Study 11425054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 232
Study 11425054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 9284850 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg single dose of sertraline (after a single dose of desipramine)
Number of subjects: 12
Study 9284850 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg single dose of sertraline (after multiple doses of desipramine)
Number of subjects: 12
Study 9284850 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg single dose of sertraline (after a single dose of imipramine)
Number of subjects: 12
Study 9284850 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg single dose of sertraline (after multiple doses of imipramine)
Number of subjects: 12
Study 8511496 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg famotidine twice daily (group 1)
Number of subjects: 440
Study 8511496 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg famotidine twice daily (group 2)
Number of subjects: 440
Study 8511496 — intervention group
Group type: COMPARATOR
Intervention: 150 mg ranitidine twice daily (group 3)
Number of subjects: 440
Study 3630806 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 40
Study 3630806 — intervention group
Group type: COMPARATOR
Intervention: Smoking Deprivation
Number of subjects: 40
Study 29113986 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg MPX (low dose)
Number of subjects: 125
Study 29113986 — intervention group
Group type: EXPERIMENTAL
Intervention: 4,000 mg MPX (high dose)
Number of subjects: 125
Study 29113986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 29113986 — intervention group
Group type: EXPERIMENTAL
Intervention: MPX (pooled treatment arms) in SOD2 Alanine/Alanine genotype patients
Number of subjects: 125
Study 29113986 — intervention group
Group type: COMPARATOR
Intervention: Control (SOD2 Alanine/Alanine genotype patients)
Number of subjects: 125
Study 27827328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment
Number of subjects: 499
Study 27827328 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotomized CBS (at CBS of 6)
Number of subjects: 499
Study 27827328 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial treatment in high CBS group
Number of subjects: 499
Study 24726142 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant sorafenib treatment for 4 weeks before tumor nephrectomy
Number of subjects: 10
Study 24726142 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched with regard to prognostic parameters)
Number of subjects: 10
Study 23746263 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intake assessment
Number of subjects: 44
Study 23746263 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy and protein intake
Number of subjects: 44
Study 23746263 — intervention group
Group type: EXPERIMENTAL
Intervention: In-patient malnutrition incidence
Number of subjects: 44
Study 23746263 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to intake
Number of subjects: 44
Study 20614124 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40/80 mg once daily
Number of subjects: 36
Study 20614124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 18413151 — intervention group
Group type: EXPERIMENTAL
Intervention: Late luteal phase in women with PMDD
Number of subjects: 29
Study 18413151 — intervention group
Group type: COMPARATOR
Intervention: Follicular phase in women with PMDD
Number of subjects: 29
Study 18413151 — intervention group
Group type: COMPARATOR
Intervention: Late luteal phase in Control women
Number of subjects: 29
Study 15882229 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP+laser
Number of subjects: 30
Study 15882229 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 30
Study 12638337 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D echocardiography (2DE)
Number of subjects: 43
Study 12638337 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical endoventriculoplasty (EVP)
Number of subjects: 43
Study 12638337 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 43
Study 10360804 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported symptom survey
Number of subjects: 808
Study 10360804 — intervention group
Group type: COMPARATOR
Intervention: Provider-reported symptom assessment
Number of subjects: 808
Study 7740570 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation
Number of subjects: 375
Study 7740570 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 375
Study 7740570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 1668907 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilute carbohydrate beverage (C)
Number of subjects: 9
Study 1668907 — intervention group
Group type: COMPARATOR
Intervention: Flavored water placebo (P)
Number of subjects: 9
Study 6812469 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% cromoglycate eye drops
Number of subjects: 33
Study 6812469 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 33
Study 6812469 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (cromoglycate and placebo)
Number of subjects: 33
Study 31896078 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity promotion program
Number of subjects: 122
Study 31896078 — intervention group
Group type: COMPARATOR
Intervention: Motor placebo activity (Control)
Number of subjects: 122
Study 30100379 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib plus topotecan
Number of subjects: 185
Study 30100379 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus topotecan
Number of subjects: 185
Study 30100379 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 185
Study 30100379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 27388862 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based observational practice (OP) including individual OP and collaborative OP (COP) groups in addition to reading materials (RMs)
Number of subjects: 30
Study 27388862 — intervention group
Group type: COMPARATOR
Intervention: Reading materials (RMs) only
Number of subjects: 30
Study 27388862 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative OP (COP)
Number of subjects: 30
Study 27388862 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual OP
Number of subjects: 30
Study 24894685 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI
Number of subjects: 1463
Study 22574612 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoleucine‐Proline‐Proline/Valine‐Proline‐Proline lactotripeptides (LTPs)
Number of subjects: 164
Study 22574612 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 164
Study 20206670 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (23vPPS) at 12 months
Number of subjects: 552
Study 20206670 — intervention group
Group type: COMPARATOR
Intervention: Not receiving 23vPPS at 12 months
Number of subjects: 552
Study 18981326 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 3790
Study 18981326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3790
Study 18981326 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone after adjustment for change in serum potassium
Number of subjects: 3790
Study 18981326 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in serum potassium
Number of subjects: 3790
Study 18981326 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone after year 1
Number of subjects: 3790
Study 16532892 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 29
Study 12094857 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsalazide (6.75 g daily)
Number of subjects: 154
Study 12094857 — intervention group
Group type: COMPARATOR
Intervention: Balsalazide (2.25 g daily)
Number of subjects: 154
Study 12094857 — intervention group
Group type: COMPARATOR
Intervention: Mesalamine (2.4 g daily)
Number of subjects: 154
Study 10379633 — intervention group
Group type: EXPERIMENTAL
Intervention: moexipril 15 mg once daily
Number of subjects: 93
Study 10379633 — intervention group
Group type: COMPARATOR
Intervention: nitrendipine 20 mg once daily
Number of subjects: 93
Study 9289465 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenazone (18 mg/kg body mass) administered orally after surgical ovariectomy
Number of subjects: 0
Study 9289465 — intervention group
Group type: COMPARATOR
Intervention: Phenazone (18 mg/kg body mass) administered orally before surgical ovariectomy
Number of subjects: 0
Study 1521399 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymeric probe
Number of subjects: 24
Study 1521399 — intervention group
Group type: COMPARATOR
Intervention: Metal probe
Number of subjects: 24
Study 6499895 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (CLON) 0.2 mg daily
Number of subjects: 20
Study 6499895 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine (MOX) 0.2 mg daily
Number of subjects: 20
Study 30842109 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cardiac exercise rehabilitation with remote electrocardiogram monitoring (REMS)
Number of subjects: 120
Study 30842109 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation without monitoring
Number of subjects: 120
Study 30082268 — intervention group
Group type: EXPERIMENTAL
Intervention: BVS (bioresorbable vascular scaffolds)
Number of subjects: 480
Study 30082268 — intervention group
Group type: COMPARATOR
Intervention: CoCr‐EES (cobalt‐chromium everolimus‐eluting stents)
Number of subjects: 480
Study 26984105 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume resistance training (HV), six sets/exercise, 70% of one maximal repetition, three times a week for 16 weeks
Number of subjects: 32
Study 26984105 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume resistance training (LV), three sets/exercise, 70% of one maximal repetition, three times a week for 16 weeks
Number of subjects: 32
Study 26984105 — intervention group
Group type: COMPARATOR
Intervention: Control group (CT, no exercise)
Number of subjects: 32
Study 26362793 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM acupuncture
Number of subjects: 34
Study 26362793 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 34
Study 26362793 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 34
Study 22463885 — intervention group
Group type: COMPARATOR
Intervention: Transjugular intrahepatic portasystemic shunt (TIPS)
Number of subjects: 132
Study 22463885 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-diameter prosthetic H-graft portacaval shunt (HGPCS)
Number of subjects: 132
Study 20506371 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 110
Study 20506371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 18336547 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium longum strains (2C and 46)
Number of subjects: 55
Study 18336547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 18336547 — intervention group
Group type: COMPARATOR
Intervention: Commercial control (Bifidobacterium lactis Bb-12)
Number of subjects: 55
Study 16116971 — intervention group
Group type: EXPERIMENTAL
Intervention: CPA + metformin (n = 25)
Number of subjects: 50
Study 16116971 — intervention group
Group type: COMPARATOR
Intervention: CPA (n = 25)
Number of subjects: 50
Study 14503550 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapeutic approaches targeting epithelial cells, myofibroblasts, and chronic inflammation
Number of subjects: 0
Study 14503550 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy of corticosteroids and cytotoxic medications
Number of subjects: 0
Study 10678454 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening for spectral shifts in ambient sound
Number of subjects: 0
Study 10678454 — intervention group
Group type: COMPARATOR
Intervention: Simulated listener motion
Number of subjects: 0
Study 8672151 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal therapy (chemotherapy and radiotherapy followed by surgery)
Number of subjects: 113
Study 8672151 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 113
Study 8672151 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal therapy
Number of subjects: 113
Study 1925820 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 20
Study 1925820 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 20
Study 1925820 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Nifedipine and Captopril)
Number of subjects: 20
Study 1925820 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (10 mg) and Captopril (25 mg)
Number of subjects: 20
Study 6388722 — intervention group
Group type: EXPERIMENTAL
Intervention: BICAP bipolar electrocoagulation treatment
Number of subjects: 129
Study 6388722 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 129
Study 6388722 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigmata of recent hemorrhage
Number of subjects: 129
Study 6388722 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality rate
Number of subjects: 129
Study 30952032 — intervention group
Group type: EXPERIMENTAL
Intervention: CHORDATA® method (body suspension and pendulum exercises)
Number of subjects: 26
Study 30952032 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study 29804953 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-strand hamstring autograft technique
Number of subjects: 64
Study 29804953 — intervention group
Group type: COMPARATOR
Intervention: Quadrupled semitendinosus-gracilis autograft
Number of subjects: 64
Study 26871851 — intervention group
Group type: EXPERIMENTAL
Intervention: Human urinary kallidinogenase for 7 days, followed by maintenance therapy of pancreatic kallikrein for 6 months
Number of subjects: 61
Study 26871851 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 25144133 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg·kg of caffeine (CAF)
Number of subjects: 16
Study 25144133 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 16
Study 22331946 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (WP) 80 mg/m² for 12 weeks followed by FEC (fluorouracil 500 mg/m², epirubicin 100 mg/m², cyclophosphamide 500 mg/m²) every 3 weeks for four cycles
Number of subjects: 601
Study 22331946 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (XT) 75 mg/m² on day 1 and capecitabine (1,500 mg/m² on days 1 through 14) every 3 weeks for four cycles followed by FEC for four cycles
Number of subjects: 601
Study 22331946 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (XT)
Number of subjects: 601
Study 22331946 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (WP)
Number of subjects: 601
Study 20644207 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline hydrochloride
Number of subjects: 101
Study 20644207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 20644207 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline hydrochloride and Placebo
Number of subjects: 101
Study 17959981 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pregabalin 100 mg
Number of subjects: 90
Study 17959981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 17321219 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Play-the-Winner (RPW) treatment allocation
Number of subjects: 0
Study 17321219 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 14722890 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol administration of Edmonston-Zagreb measles vaccine (10^3.6 pfu/dose)
Number of subjects: 100
Study 14722890 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous administration of Edmonston-Zagreb measles vaccine (10^4.27 pfu/dose)
Number of subjects: 100
Study 14722890 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol administration of Edmonston-Zagreb measles vaccine
Number of subjects: 100
Study 14722890 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous administration of Edmonston-Zagreb measles vaccine
Number of subjects: 100
Study 11288792 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD + AB (Enamel Matrix Proteins + Antibiotics)
Number of subjects: 34
Study 11288792 — intervention group
Group type: COMPARATOR
Intervention: EMD (Enamel Matrix Proteins)
Number of subjects: 34
Study 9709314 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedic assessment of clinical indicators of c-spine injury
Number of subjects: 20
Study 9709314 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedic assessment of alteration in consciousness
Number of subjects: 20
Study 9709314 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedic assessment of evidence of intoxication
Number of subjects: 20
Study 9709314 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedic assessment of complaint of neck pain
Number of subjects: 20
Study 9709314 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedic assessment of cervical tenderness
Number of subjects: 20
Study 9709314 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedic assessment of neurologic deficit or complaint
Number of subjects: 20
Study 9709314 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedic assessment of distracting injury
Number of subjects: 20
Study 8422488 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood conservation techniques including withdrawal of blood before surgery, intraoperative blood salvage with Solcotrans, and profound hemodilution
Number of subjects: 28
Study 8422488 — intervention group
Group type: COMPARATOR
Intervention: Profound hemodilution only during cardiopulmonary bypass (CPB)
Number of subjects: 28
Study 8422488 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood conservation techniques
Number of subjects: 28
Study 3521856 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoximetasone gel 0.05%
Number of subjects: 125
Study 3521856 — intervention group
Group type: COMPARATOR
Intervention: Fluocinonide gel 0.05%
Number of subjects: 125
Study 31189129 — intervention group
Group type: EXPERIMENTAL
Intervention: Procollagen type 1 N-terminal propeptide
Number of subjects: 15
Study 31189129 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon-like peptide-2
Number of subjects: 15
Study 31189129 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-dependent insulinotropic peptide
Number of subjects: 15
Study 31189129 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerostin
Number of subjects: 15
Study 28241237 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel (dose adjusted to maintain normal testosterone levels for young men)
Number of subjects: 788
Study 28241237 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Number of subjects: 788
Study 28241237 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 788
Study 25853877 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (25 g/d for the first 5 days followed by 5 g/d for 8 weeks)
Number of subjects: 60
Study 25853877 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same amount as creatine for 8 weeks)
Number of subjects: 60
Study 25853877 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation or exercise)
Number of subjects: 60
Study 24043457 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal patch containing 0.55 mg ethinyl estradiol and 2.1 mg gestodene
Number of subjects: 30
Study 24043457 — intervention group
Group type: COMPARATOR
Intervention: Monophasic oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel
Number of subjects: 30
Study 21823917 — intervention group
Group type: EXPERIMENTAL
Intervention: computer-delivered brief intervention
Number of subjects: 50